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 Guanabenz inhibits TLR9 signaling through a pathway
that is independent of eIF2a dephosphorylation
by the GADD34/PP1c complex
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Endoplasmic reticulum (ER) stress triggers or amplifies inflammatory signals and cytokine production in immune
cells. Upon the resolution of ER stress, the inducible phosphatase 1 cofactor GADD34 promotes the dephosphorylation
of the initiation factor eIF2a, thereby enabling protein translation to resume. Several aminoguanidine compounds,
such as guanabenz, perturb the eIF2a phosphorylation-dephosphorylation cycle and protect different cell or
tissue types from protein misfolding and degeneration. We investigated how pharmacological interference with
the eIF2a pathway could be beneficial to treat autoinflammatory diseases dependent on proinflammatory cyto-
kines and type I interferons (IFNs), the production of which is regulated by GADD34 in dendritic cells (DCs). In mouse
and human DCs and B cells, guanabenz prevented the activation of Toll-like receptor 9 (TLR9) by CpG oligodeoxy-
nucleotides or DNA-immunoglobulin complexes in endosomes. In vivo, guanabenz protected mice from CpG oligo-
nucleotide–dependent cytokine shock and decreased autoimmune symptom severity in a chemically induced model
of systemic lupus erythematosus. However, we found that guanabenz exerted its inhibitory effect independently of
GADD34 activity on eIF2a and instead decreased the abundance of CH25H, a cholesterol hydroxylase linked to anti-
viral immunity. Our results therefore suggest that guanabenz and similar compounds could be used to treat type I
IFN–dependent pathologies and that CH25H could be a therapeutic target to control these diseases./stk
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The immunomodulating functions of dendritic cells (DCs), such as
antigen presentation, are considerably enhanced after detection of cell
damage–associated or pathogen-associated molecular patterns (PAMPs).
Toll-like receptors (TLRs) have a major role in recognizing and initi-
ating inflammatory or immune responses to PAMPs such as lipopoly-
saccharide (LPS) or nucleic acids (1). Most TLRs detect their ligand at
the cell surface, except for TLR3, TLR7, TLR8, and TLR9, which are
found in endosomes (2), where they are proteolytically activated and
mediate nucleic acid recognition and signal transduction (3, 4). TLR7
and TLR9, whose ligands are, respectively, single-stranded RNA and
DNA with unmethylated cytosine-phosphate-guanine (CpG) motifs
(5, 6), are expressed in a restricted subset of immune cells, including
B cells or plasmacytoid DCs (pDCs), which specialize in the produc-
tion of type I interferon (IFN) (7). TLR9 and its DNA ligands must have
access to specific endosome subsets to allow the recruitment and
activation of the MyD88/IFN regulatory factor 7(IRF7)–dependent
signaling pathway and to initiate type I IFN production (8). In path-
ological contexts, improper stimulation of endocytic TLRs by self–
nucleic acids drives a feedforward positive inflammatory amplification
loop, during which B cell–dependent secretion of autoantibodies and
pDC activation by nucleic acid–immunoglobulin (Ig) complexes fuel
the continuous release of pathogenic levels of type I IFN (7). TLR7-
and TLR9-expressing pDCs and B cells are therefore key cellularplayers in the establishment and progression of several type I IFN–
dependent diseases such as systemic lupus erythematosus (SLE) or
Sjögren syndrome (9, 10).
The signaling cascades that regulate endoplasmic reticulum (ER)
homeostasis and promote cell survival are collectively known as the
integrated stress response (ISR) (11). Cross-talk between TLR signal-
ing pathways and the ISR has been uncovered (12), in which the ISR
provides an amplification signal that favors activation of nuclear
factor kB (NF-kB) and IRFs and that increases type I IFN or inflam-
matory cytokine production. Among the ISR signaling modules in-
volved in this cross-talk, the phosphorylation of the a subunit of
eukaryotic translation initiation factor 2 (eIF2a) at Ser51 is particu-
larly important (13, 14). This phosphorylation event, which can be
executed by four different eIF2 kinases (PERK, PKR, GCN2, and
HRI), inhibits the guanine nucleotide exchange factor eIF2B and
results in reduced translation initiation and diminished production of
newly synthesized proteins (15). Growth arrest and DNA damage–
inducible protein 34 (GADD34; also known as PPP1R15A) (16, 17) is
a key ISR-inducible cofactor that promotes the dephosphorylation
eIF2a through its association with protein phosphatase 1 catalytic sub-
unit (PP1c) and restores normal protein synthesis after the translational
arrest initiated by the activation of kinases that phosphorylate eIF2a.
GADD34 is required for the production of several inflammatory cyto-
kines by double-stranded RNA (dsRNA)–activated DCs, including
IFN-b and interleukin-6 (IL-6) (14), and accordingly,GADD34-deficient
mice cannot efficiently control viral infection (13, 14). GADD34 induc-
tion also attenuates LPS-induced sepsis and acute tissue injury in mouse
by suppressing macrophage activation (18).
Pharmacological interference with GADD34 could be an attract-
ive solution for inflammatory pathologies. Guanabenz [GBZ; 2-(2,6-
dichlorobenzylidene)hydrazinecarboximidamide] has been proposed
to specifically inhibit GADD34 activity by disrupting its interaction1 of 13
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cells from lethal protein misfolding and treat diseases like amyo-
trophic lateral sclerosis (20). Originally, GBZ was developed as a small
a2-adrenergic receptor agonist (trade name: Wytensin) that is well tol-
erated and received U.S. Food and Drug Administration approval for the
treatment of hypertension (21). GBZ also has some anti-inflammatory
properties in different pathological situations, includingmultiple sclero-
sis (22). The capacity ofGBZ and of its derivative Sephin 1 to specifically
inhibit the GADD34-holophosphatase complex has been challenged
(23), although treated cells show increased eIF2a phosphorylation
and reduced protein synthesis activity. Given this ongoing controversy,
we explored the impact of GBZ on TLR signaling relative to GADD34
activity using cells and animals expressing a nonfunctional form of
the PPP1R15A gene (GADD34DC/DC) (24). Here, we confirmed that
GADD34 inactivation inhibited the capacity of PAMP-activated DCs to o
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 produce type I IFN and proinflammatory
cytokines in vitro and that pharmacological
treatment with GBZ mostly recapitulated
this genetic phenotype. However, GBZ also
blocked TLR9-dependent activation by
DNA in B cells and DCs independently
of the presence of functional GADD34.
These observationswere confirmed invivo,
whereGBZprotected bothwild-type (WT)
and GADD34DC/DC mice from the lethal
cytokine shock caused byCpGoligodeoxy-
nucleotide (ODN) injection after liver sen-
sitization with D-galactosamine (D-GalN).
GBZ injections also efficiently reduced cir-
culating anti–nucleic acid antibody titer
and lipogranuloma formation in the type
I IFN–dependent tetramethylpentadecane
(TMPD)–inducible SLE mouse model (25),
suggesting that GBZ could potentially be
used to treat type I IFN–mediated path-
ologies. Finally, we found that GBZ acts
by reducing the expression of the choles-
terol hydroxylase CH25H, revealing the
importance of its enzymatic product 25-
hydroxycholesterol (25-HC) for normal
TLR9 intracellular sorting and signaling
from endosomes during human pDC ac-
tivation by CpG DNA.RESULTS
GBZ treatment partially
phenocopies GADD34 genetic
inactivation in DCs
We have previously shown that IFN-b and
IL-6 production in response to the dsRNA
mimic polyriboinosinic:polyribocytidylic
acid [poly(I:C)] is defective in granulocyte-
macrophage colony-stimulating factor
(GM-CSF)–induced bone marrow (BM)–
derived DCs from GADD34DC/DC mice
(14). We investigated whether this obser-
vation could be extended to other DC
subsets and other TLR ligands. WT andPerego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018GADD34DC/DC DCs isolated directly from spleen or generated in vitro
from BM progenitors, using either Flt3L- or GM-CSF–induced differ-
entiation, were stimulated with LPS, poly(I:C), or CpG ODN. Flt3L-DCs
are well suited for these in vitro experiments because they encompass
all the main DC subsets (DC1, DC2, and pDCs) found in vivo and pref-
erentially express TLR3, TLR4, or TLR9 (26). After poly(I:C) stimula-
tion, Flt3L-DCs lacking functional GADD34 showed reduced IFN-b
and IL-6 production (Fig. 1, A and B), confirming the cytokine deficit
observed in GADD34DC/DC GM-CSF DCs (Fig. 1, C and D). IFN-b
and IL-6 production in response to LPS was not affected by GADD34
deficiency in GM-CSF DCs. However, IFN-b secretion was augmented
whereas IL-6 secretion was decreased in GADD34DC/DC Flt3L-DCs (Fig. 1,
A to D). When compared to in vitro–generated cells, CD11c+ DCs di-
rectly isolated from mouse spleen were also sensitive to GADD34 inac-
tivation (Fig. 1, E and F). However, IL-6 production was less effectivelyFig. 1. GBZ mimics GADD34 inactivation and impairs TLR3 and TLR9 signaling. (A to F) Bone marrow–derived
Flt3L-DCs (dendritic cells) (A and B), bone marrow–derived granulocyte-macrophage colony-stimulating factor (GM-CSF)
DCs (C and D), and splenic DCs (E and F) from wild-type (WT) or GADD34DC/DC (DC/DC) mice were stimulated for 6 hours
with lipopolysaccharide (LPS) (100 ng/ml; from Escherichia coli), low–molecular weight (LMW) poly(I:C) (pI:C; 10 mg/ml), or
1 mM ODN 1585. NT, nontreated. Guanabenz (GBZ) was added at 50 mM. The concentrations of secreted interferon-b
(IFN-b) (A, C, and E) or interleukin-6 (IL-6) (B, D, and F) were measured by enzyme-linked immunosorbent assay (ELISA).
Statistical significance was assigned using two-tailed t test on at least three independent experiments (*P < 0.05; **P <
0.005; ***P < 0.0005). N.D., not detected; N.S., not significant.2 of 13
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 inhibited, suggesting that the effect varies according to the cell type
studied and the stimulation or differentiation conditions used.
We next tested the effect of treating DCs with GBZ, a small com-
pound that reportedly inhibits the GADD34/PP1c interaction (19).
For IL-6 production, GBZ had an effect similar to that of GADD34
inactivation. However, we noticed that GBZ more strongly inhibited
IFN-b production in response to TLR9 stimulation than did GADD34
genetic inactivation (Fig. 1, A to F). This effect was particularly acute
upon CpG ODN stimulation of GADD34DC/DC Flt3L-DCs, which were
incapable of producing IFN-b or IL-6 upon GBZ treatment, which
also synergized with the lack of functional GADD34 (Fig. 1, A and B).
These additive effects also suggested that GBZ interferes with proteos-
tasis independently of GADD34/PP1c binding, as has been proposed
by Crespillo-Casado and collaborators (23).
GBZ inhibits DC activation by poly(I:C) and CpG ODN
We decided to further investigate the strong inhibition of TLR3 and
TLR9 by GBZ. Among mouse DC subsets, TLR3 and TLR9 are most
abundant inCD8+-like conventionalDCs (cDC1) and in pDCs (26, 27).
Mouse CD11c+/MHCII+ (major histocompatibility complex class II–
positive) DCs from Flt3L-treated BM cultures were sorted as cDC1
(CD24+/Sirpa−), cDC2 (CD11b+/Sirpa+), and pDC (BST2+/Siglec H+/
B220+) (Fig. 2A). Sorted TLR3-expressing cDC1 were activated with
low–molecular weight (LMW) poly(I:C), and TLR9-expressing pDCs o
n
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ag.org/were stimulated with CpG-A ODN. In
both cases, GBZ treatment nearly abro-
gated cytokine production and IFN-b
and IL-6 secretion by pDCs in particular
(Fig. 2B) without affecting cell viability.
GBZ also completely inhibited the transcrip-
tional response to CpG ODN, as judged
by the loss of the expression of key genes
in pDCs, including IFNA4, TNF, ISG15,
and IL12B, as monitored by quantitative
polymerase chain reaction (qPCR) (Fig.
2C), and the lack of surface CD86 and
CD69 up-regulation after mouse primary
B cell activation (fig. S1A).
We next evaluated GBZ-mediated in-
hibition on NF-kB signaling by monitor-
ing secreted alkaline phosphatase (SEAP)
reporter levels in human embryonic kid-
ney (HEK)–293 cells expressing various
human TLRs (Fig. 3A). As expected, GBZ
treatment inhibited TLR3-, TLR7-, and
TLR9-dependent activation of the SEAP
reporter, but not of that by TLR4.We next
treated freshly isolated BDCA4+/CD123+
human primary blood pDCs activated with
either CpG-A– or DNA-IC–containing
serum from lupus patients (Fig. 3B). GBZ
prevented the production of type I IFN and
tumor necrosis factor–a (TNF-a) by stim-
ulated human pDCs independently of the
ligands used. Similarly, GBZ inhibited
TNF-a secretion and cytokine expression
at the mRNA level in the human CAL-
1 pDC line (Fig. 3C) (28) and in primary
human B cells (fig. S1B). The functionalityPerego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018of the TLR9 transduction pathway was next evaluated by using flow cy-
tometry to detect the phosphorylation of 40S ribosomal protein S6, an
early signaling event downstream of TLR activation by LPS or viruses
(29, 30). GBZ-treated CAL-1 and human B cells both displayed a reduc-
tion in S6 phosphorylation that was normally induced after CpG expo-
sure (Fig. 3Dand fig. S1C), suggesting thatGBZ inhibits an upstream step
in the TLR9 signal transduction pathway.
GBZ protects mice from CpG ODN–induced cytokine shock
independently of GADD34
In addition to its hypotensive indications in humans, the therapeutic
potential of GBZ for misfolded protein stress-associated diseases has
been tested in mice (22), primarily in neurodegenerative diseases
characterized by both neuronal degeneration and inflammation. De-
spite conflicting results (22, 31, 32), these mouse experiments have
yielded important pharmacokinetics data on GBZ, including a plas-
ma half-life of 1.8 hours and a spinal cord accumulation of about 7 mM
several hours after a single intraperitoneal bolus injection of 2 mg/kg.
We decided to test GBZ-mediated inhibition of TLR9 by injecting
CpG ODN into mice after liver sensitization with D-GalN. Less than
20% of CpG-injected animals survived 48 hours after injection (Fig. 4A).
This survival rate was not substantially changed by coinjection with
clonidine [N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine],
a different a2-adrenergic receptor agonist without GADD34 inhibitoryFig. 2. GBZ inhibits TLR9 activation in mouse Flt3L-DCs. (A) Sorting strategy for bone marrow–derived Flt3L-
DCs. (B) IFN-b and IL-6 secretion in sorted DC1 and plasmacytoid DCs (pDCs) activated for 6 hours with LMW poly(I:C)
(10 mg/ml) or 1 mM ODN 1585, respectively. GBZ was added at 50 mM. (C) Sorted pDCs were also analyzed for the transcrip-
tional induction of genes encoding ISGs (IRF7 and ISG15) and cytokines (IFNA4, IL12B, IL6, and TNF) at different time points.
Data are represented as fold increase compared to untreated pDCs. Statistical significance was assigned using two-tailed
t test on at least n = 3 independent experiments (*P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001).3 of 13
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 activity (33). Clonidine was therefore used as a control compound
throughout our study to evaluate the impact of the inhibition of a2-
adrenergic receptor signaling and hypotension on the general toxicity
induced by D-GalN andCpG injections. Coinjection ofGBZwithCpG
increased survival up to 70%. However, GADD34DC/DC mice were as
sensitive as WT animals to D-GalN and CpG injections and were also
protected from death by GBZ treatment (Fig. 4B). Therefore, GBZ in-
hibits TLR9 in vivo independently of GADD34, although with decreased
efficiency (−28%), suggesting cross-talk between GBZ-induced proteos-Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018tasis and GADD34 inactivation that favors
survival in this pathological model.
In WT animals, GBZ treatment de-
creased circulating TNF-a and IL-6 plas-
ma concentrations (Fig. 4C). Although
circulating type I IFN remained undetect-
able, production of the anti-inflammatory
cytokine IL-10 was increased, suggesting
that GBZ could exert protective effects by
reinforcing secondary anti-inflammatory
responses in vivo (Fig. 4C). Although
much less efficient than GBZ, clonidine
had some inhibitory effect on TNF-a and
IL-6 production after 1 hour, but this in-
hibition was not observed after 3 hours
(Fig. 4C), suggesting that hypotension
could contribute to reduce the diffusion
of inflammatory cytokines for a short pe-
riod after injection. In the D-GalN model,
LPS-induced lethality is triggered by a
caspase-dependent fulminant apoptotic
hepatitis induced by TNF-a overproduc-
tion and not directly from the systemic
inflammatory response (34). However,
in this model of CpG-induced lethality,
liver examination and histological scores
indicated that GBZ did not increase he-
patic cell survival (Fig. 4D) and that its
activity was most likely exerted through
the inhibition of proinflammatory cyto-
kine release by immune cells and not by
hepatocytes.
GBZ protects mouse from
TMPD-induced autoimmunity
TMPD (pristane) intraperitoneal injec-
tion induces an SLE-like disease in mice
(25). In this pathological model, glomer-
ulonephritis and autoantibody produc-
tion strictly depend on signaling through
the IFN-a/b receptor (IFNAR) and the
formation of “lipogranulomas,”which rep-
resent a chronic inflammatory response to
TMPD and are the sites of autoantibody
production (25, 35). Monocytes are re-
cruited to the inflamed peritoneal cavity
where they are activated by endogenous
TLR7 and, potentially, TLR9 ligands and
are the major sources of type I IFN in
this model, which, after a period of 3 to4 months, results in different autoimmune manifestations specific to
the mouse genetic background (25, 36, 37). The TMPD-inducible SLE
model appears, therefore, to be particularly suitable for testing GBZ
inhibitory activity on endosomal TLRs in vivo, because it is inducible
and type I IFN–dependent and mimics some human SLE features
(38). We modified the original protocol of TMPD-induced SLE (36)
by adding an intraperitoneal injection of CpG ODN to boost TLR9-
dependent activation and reinforce type I IFN production that should
be counteracted by GBZ treatment (Fig. 5A). CpG injection alone hadFig. 3. GBZ impairs TLR9 signaling in human cells. (A) Human Toll-like receptor 4 (hTLR4), hTLR3, hTLR9, and
hTLR7 reporters expressed in HEK-Blue cells were activated with LPS (100 ng/ml), LMW poly(I:C) (10 mg/ml), 2.5 mM
ODN 2006, or imiquimod (5 mg/ml), respectively. HEK-293, human embryonic kidney 293 cells; OD 405 nm, optical
density at 405 nm. GBZ was added at 50 mM. TLR activity was measured indirectly through secreted alkaline phos-
phatase (SEAP) activity as absorbance at 405 nm. (B) Human primary pDCs were isolated from blood and activated
either with 3 mM ODN 2216 or 2% serum from lupus patients. GBZ was added at 50 mM. Secreted IFN-a and tumor
necrosis factor–a (TNF-a) were measured at the indicated time points or at 16 hours. (C) CAL-1 cells were stimulated
with 3 mM ODN 2216. GBZ was added at 50 mM. Secreted TNF-a was measured 3 hours after activation. Gene expression
of TNF and IFNA2 were measured by quantitative polymerase chain reaction (qPCR) and normalized on untreated cells.
(D) Mean fluorescence intensity (MFI) for phospho-ribosomal protein S6 (P-S6) detected by intracellular phospho-flow
cytometry in CpG-A–activated CAL-1 cells treated or not with GBZ. Data of three experiments were normalized to those
from nontreated cells. Statistical significance was assigned using two-tailed t test on at least three independent
experiments (*P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001).4 of 13
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 a comparable effect as TMPD on the recruitment of different inflam-
matory cell populations, in particular Ly6G+ neutrophils and Ly6C+
monocytes, which were enriched in peritoneal exudate cells (PECs)
at day 14 (fig. S2A), suggesting that the two treatments could syn-
ergize, as demonstrated by the increased type I IFN signature observed
immediately after CpG injection (fig. S2B).
Flow cytometry analysis of PECs from TMPD/CpG-injected C57BL/6
mice revealed that, as expected, TMPD/CpG treatment decreased
peritoneal B cell numbers (CD11bdim/−/CD19+) while concomitantly
increasing the recruitment of neutrophils (Ly6G+/CD11b+) and in-
flammatory monocytes (Ly6C+) (Fig. 5, B and C). GBZ injections
did not prevent immune cell migration into or from the peritoneal
cavity, indicating that the drug did not affect this key step in TMPD-Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018induced pathology (Fig. 5, B and C). We
next attempted tomeasure IFN-stimulated
gene (ISG) expression in peritoneal cells
of two different mouse cohorts (Fig. 5D).
The expression of TNF-a and of type I
IFN–inducible ISG15 and CH25H genes
were induced inPECs isolated fromTMPD-
and CpG-injected mice compared to con-
trol littermates. These transcriptional
responses, indicative of both ongoing in-
flammation and type I IFN production,
were inhibited by recurrent GBZ injections
(Fig. 5D). TMPD-treatedC57BL/6mice are
biased to generate anti-ribonucleoprotein
or RNA autoantibodies rather than anti-
DNA autoantibodies in the long term (25).
Titers of circulating antinuclear and anti-
RNA Ig plasma concentration in response
toTMPD injectionwere substantially lower
in GBZ-treated mice than in animals in-
jected with TMPD and CpG only (Fig. 5E).
In agreement with these data, the perito-
neal cavity of GBZ-treatedmice contained
considerably fewer plasma cell–containing
lipogranulomas, explaining the lower cir-
culating concentration of autoantibodies
and confirming the inhibitory activity of
GBZ on the activity of endocytic TLRs (Fig.
5D). As expected in C57BL/6 mice (25),
anddespiteadditionalCpGODNtreatment,
we could not induce sufficient glomerulo-
nephritis overall to observe significant
differences in the levels of Ig complex de-
posits in the kidneys of control and GBZ-
treated animals. Together, these data
support the efficacy ofGBZas an inhibitor
of nucleic acid activation of TLRs in vivo.
CH25H expression is
down-modulated by GBZ
To identify the GBZ-mediated molecu-
lar mechanisms that inhibit TLR signal-
ing, we tested various hypotheses. To test
for the unlikely role for a2-adrenergic
receptor agonism in this process, we as-
sessed the effect of clonidine on TLR9inhibition in vitro. In contrast to GBZ, clonidine did not attenuate
the increase in CD86 and CD69 in CpG-stimulated splenic B cells
(fig. S1A). These results ruled out a major role for a2-adrenergic re-
ceptor activation in controlling TLR9 signaling. Because of the impor-
tance of endosomal acidification and proteolysis for endocytic TLR
activation, we next tested whether GBZ interferes with these basic
functions, as previously observed for chloroquine and bafilomycin,
two inhibitors of endosome acidification and endocytic TLR activity
(fig. S3, A and B). Monitoring of endosome acidification in HEK-293
cells by flow cytometry and fluorescein isothiocyanate fluorescence
quenching assay (39) revealed that GBZ did not affect acidification, un-
like the positive control bafilomycin (fig. S3A). As an alternative mea-
surement of endosomal proteolysis, we assessed the cathepsin-dependentFig. 4. GBZ rescues mice from TLR9-dependent cytokines shock. (A and B) WT (A) and GADD34DC/DC (B) mice were
injected with D-GalN (20 mg per mouse), ODN 1826 or phosphate-buffered saline (PBS) for control mice (50 mg/20 g),
and GBZ or clonidine (Clo; 2 mg/kg). Survival is represented as total percentage of survival after 48 hours (left) or in a
Kaplan-Meier plot (right). (C) The concentrations of circulating TNF-a, IL-10, and IL-6 were measured at 1 and/or 3 hours.
(D) Liver tissue damage (histological score) was determined in a blinded fashion by a pathologist. Statistical significance
was assigned on sample comparison by a one-way analysis of variance (ANOVA), followed by Tukey range test, and on
the survival curve using log-rank test, followed by Benjamini-Yekutieli correction (*P < 0.05; **P < 0.005; ***P <
0.0005.). n values in the figure indicate the number of mice.5 of 13
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 degradation of the MHCII-associated invariant chain (also known as Ii
or CD71), which occurs rapidly inmouseA20B cells (40). In contrast to
chloroquine, which caused accumulation of the characteristic Ii proteo-
lytic intermediates p10 and p22 (fig. S3B), GBZ did not affect Ii endo-
somal degradation even with prolonged treatment. We also asked
whether the increase in eIF2a phosphorylation triggered by GBZ in
mouse DCs (fig. S3C) could inhibit protein synthesis and influence di-
rectly cytokine production.We therefore optimized the puromycylation
procedure “SUNSET” to quantify protein synthesis by intracellular flow
cytometry (41). As expected from our previous work onGADD34DC/DC
DCs (14), GBZ did not alter mRNA translation in CpG-activated pDCs
(fig. S3D) and was therefore unlikely to affect TLR signaling and cyto-
kine production by directly inhibiting protein synthesis.
In the absence of obvious mechanistic clues explaining the inhibitory
effect of GBZ on TLR signaling, we initiated an unbiased comparative
microarray-based genomic analysis on purified GM-CSF CD11c+ DCs,
stimulated with Proteus mirabilis extract (a TLR4 ligand) or poly(I:C)Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018(a TLR3 ligand) in the presence or absence of GBZ. We used these
experimental conditions instead of stimulating with CpG ODN, be-
cause they trigger substantial, but less extreme, responses to GBZ treat-
ment than does CpG exposure. Thus, a transcriptomic analysis
performed in these samples was more likely to reveal subtle gene ex-
pression differences that would likely be difficult to detect upon the
complete shutdown of TLR9 signaling and type I IFN secondary re-
sponses induced by GBZ. Principal components analysis showed a
close proximity of replicates without a clear partitioning of GBZ-treated
cells from activated controls (Fig. 6A). Reflecting this analysis, only a
few genes, identified among those with the greatest increase in expres-
sion (>10-fold change), showed reduced expression upon GBZ treat-
ment (table S1). In addition to the genes encoding type I IFNs and
several ISGs, cholesterol 25 hydroxylase (CH25H) expression was the
most significantly affected by GBZ upon P. mirabilis and poly(I:C)
stimulation (60 and 90% of inhibition, respectively). Ch25h is induced
by type I IFNs downstream of TLR3 or TLR4 activation (42), and theFig. 5. GBZ decreases the severity lupus-like symptoms in the pristane injection model. (A) The experimental protocol: Mice were injected at day 0 (D0) with PBS
or 500 ml of tetramethylpentadecane (TMPD) and then injected every 2 days for 2 weeks with PBS/dimethyl sulfoxide (DMSO) or GBZ (2 mg/kg). At day 7, mice were
injected with ODN 1585 (50 mg/20 g). Blood was collected monthly to determine the circulating autoantibody level. Mice were sacrificed at week 24 (W24) after disease
induction. (B and C) Flow cytometry analysis of peritoneal exudate cell (PEC) populations at day 14. (D) Mice were sacrificed at week 24, and gene expression of IFN-
stimulated genes (ISGs) and cytokines in PECs was determined by qPCR. Statistical significance was assigned using two-tailed Student’s t test (*P < 0.05). (E) Level of
circulating anti-RNA antibodies (normalized to control mice), antinuclear antibodies (arbitrary units), the presence of lipogranulomas in the peritoneal cavity (arbitrary
score), and glomerulopathy (histological score was determined in a blinded fashion by a pathologist) at week 24. Statistical significance was assigned by a one-way
ANOVA, followed by Tukey range test (*P < 0.05; **P < 0.005; ***P < 0.0005). n values in the figure indicate the number of mice.6 of 13
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 enzyme encoded by this gene transforms cholesterol into 25-HC.
CH25H inactivation protects against influenza infection in mice be-
cause of decreased inflammatory-induced pathology (43). Furthermore,
its enzymatic product, 25-HC, amplifies inflammation through numer-
ous immunological effects, including suppressing IgA production (44)
and B cell migration (45).
CH25H activity and 25-HC accumulation also inhibit the sterol
regulatory element–binding protein (SREBP)–dependent expression
of cholesterol synthesis pathway genes (45) and affect cholesterol ho-Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018meostasis during viral activation (46). As anticipated from CH25H in-
duction, the mRNA expression of most cholesterol synthesis genes
(Fig. 6B) was decreased during DC activation but remained un-
changed upon GBZ cotreatment (Fig. 6C). This inverse correlation be-
tween Ch25h transcription and SREBP-dependent gene expression
suggests that GBZ prevented the feedback repression on SREBP nor-
mally mediated by 25-HC synthesis. This conclusion was also sup-
ported by the decreased expression of MYLIP and ABC1 (Fig. 6C),
whose gene products are involved in cholesterol transport and showFig. 6. GBZ reduces TLR-dependent Ch25h induction. (A) Principal components (Comp) analysis generated from microarray gene expression studies comparing
GM-CSF DCs activated for 8 hours with high–molecular weight (HMW) poly(I:C) or P. mirabilis, with or without GBZ. (B) Graphical representation of the cholesterol
biosynthesis pathway and its regulation with regard to CH25H, SREBP (sterol regulatory element–binding protein), GBZ, and TLRs. (C) List of genes involved in the
cholesterol biosynthesis and their expression fold change (Fc) compared to untreated control cells. na, not applicable. (D) TLR9, GADD34, and ATF3 mRNA expression
in mouse spleen pDCs activated with 1 mM ODN 1585. CH25H mRNA level in GM-CSF DCs activated for 8h with LPS (100 ng/ml), HMW poly(I:C) (10 mg/ml), or 1 mM
ODN 1585, with or without GBZ (50 mM) (bottom). (E) CH25H mRNA (left) and IL-6 secretion (right) levels in WT and GADD34DC/DC Flt3L-DCs treated with CpG and GBZ,
exposed or not to exogenously added type I IFN. Statistical significance was assigned using two-tailed t test on at least three independent experiments (*P < 0.05; **P <
0.005; ***P < 0.0005; ****P < 0.0001).7 of 13
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 increased expression upon CH25H-dependent cholesterol shortage
induced by IFN (46). GADD34 and ATF3 expression were increased
by GBZ treatment, whereas that of TLR9 remained stable, presum-
ably due to the absence of IFN in the GBZ-treated cell culture (Fig. 6D
and fig. S4A). Activating transcription factor 3 (ATF3) is therefore
regulated in a stress-dependent manner by GBZ, which is an impor-
tant observation because ATF3 inhibits TLR-induced cytokine produc-
tion in macrophages (47), an activity that is partially mediated through
direct repression of Ch25h transcription (48).
qPCR analysis of spleen pDCs revealed a strong induction of CH25H
in response to CpG stimulation, which was repressed by GBZ (Fig. 6D),
thus confirming the microarray analysis of BM-DCs. We next com-
pared the capacity of WT and GADD34DC/DC Flt3L-DCs to produce
cytokines and express Ch25h when exposed to exogenously added
type I IFN (Fig. 6E). The addition of IFN to cultured DCs did not af-
fect the secretion of IL-6 by CpG-activated cells and did not reverse
the strong inhibition mediated by GBZ. IFN alone induced a moderate
increase in Ch25h expression that was not inhibited by GBZ treatment,
whereas CpG induction of Ch25h expression was highly sensitive to
GBZ, showing the absence of a true synergetic effect between exoge-
nous IFN addition and CpG on Ch25h mRNA expression (Fig. 6E).
The lack of type I IFN production in GBZ-treated CAL-1 cells was there-
fore not the primary reason for the inhibition of Ch25h expression,
which occurred independently of GADD34 activity (Fig. 6E).
Transport of TLR9 to signaling endosomes is inhibited
by GBZ and controlled by 25-HC
25-HC can induce the ISR (44), and altered cholesterol levels at the
TGN (trans-Golgi network)/endosome boundaries affect recycling en-
dosome dynamics (45). We thus hypothesized that by repressing CH25H
expression in CpG-stimulated DCs, GBZ could block the paracrine
activity of 25-HC or altered their cholesterol metabolism, thereby chang-
ing intracellular trafficking and subsequent signaling by endocytic
TLR9 (37). We therefore investigated whether the effect of GBZ on
the intracellular sorting of TLR9 to endosomes was caused by a reduc-
tion of 25-HC levels and associated changes in cholesterol metabolism.
We first observed that the lack of type I IFN production after GBZ
treatment did not attenuate TLR9 expression in CAL-1 cells as shown
by both qPCR (fig. S4A) and surface flow cytometry measurement
(fig. S4B), thus ruling out a direct impact of 25-HC on the DNA sensing
ability of the cells. We used immunofluorescence proximity ligation
assay (iPLA) to monitor TLR9 and MyD88 association in type I IFN
signaling endosomes (49). As expected, iPLA interactions between TLR9
and the signaling adaptor MyD88 and between TLR9 and the tran-
scription factor IRF7 were strongly increased by CpG stimulation
(Fig. 7A). These close associations (<40 nm) were likely to occur in
VAMP3+ sorting endosomes, because a strong association of TLR9
with VAMP3 was also observed at the time of MyD88 and IRF7 re-
cruitment (Fig. 7A) (49). GBZ treatment impaired the recruitment of
TLR9 to VAMP3+ endosomes and the interaction of TLR9 with
MyD88 and IRF7, the endpoint transcription factor required for type
I IFN induction by pDCs (Fig. 7A). Therefore, GBZ likely prevents the
transport of TLR9 to signaling endosomes and further downstream
signal transduction. We next evaluated the role of 25-HC on TLR9
expression, trafficking, and signaling. Adding exogenous 25-HC to
CAL-1 cells increased TLR9 expression by 25% (fig. S4B), endosomal
sorting (Fig. 7B), and association with MyD88 (Fig. 7B), suggesting
that 25-HC potentiated TLR9 activation in the absence of CpG stim-
ulation. 25-HC reversed the inhibitory activity of GBZ on Myd88 andPerego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018IRF7 recruitment by TLR9 (Fig. 7B) and augmented ribosomal pro-
tein S6 phosphorylation, indicative of the reestablishment of TLR9-
dependent early signal transduction (Fig. 7C). In line with these
observations, 25-HC led to a modest increase in TNF-a mRNA ex-
pression (fig. S4C) and secretion in the presence or absence of GBZ
(Fig. 7D). Together, these data suggest that in human pDCs, GBZ
inhibits TLR9 signaling by interfering with its intracellular sorting
to endosomal compartment, which partially depends on the syn-
thesis of 25-HC.DISCUSSION
Upon induction, GADD34 recruits the catalytic subunit of PP1c to
dephosphorylate eIF2a, allowing protein synthesis to resume in a
negative feedback loop that terminates UPR (unfolded protein re-
sponse) signaling. We have demonstrated that GADD34 also regu-
lates proinflammatory cytokine and type I IFN expression, both at
the transcriptional and translational levels (13, 14). GADD34 is
therefore part of the “antimicrobial stress response,” which uses stress
signaling cascades to potentiate innate immune responses (12). The
GADD34/PP1c complex has been proposed to act directly on MAPK
(mitogen-activated protein kinase) and NF-kB signaling by dephos-
phorylating TAK1 (transforming growth factor–b–activated kinase 1)
at Ser412, which inhibits production of TNF-a and IL-6 upon TLR ac-
tivation (50). This model has not been confirmed, but instead, de-
activation of the kinase IKK by GADD34/PP1c has been proposed as
an alternative means of controlling LPS-mediated activation of macro-
phages (18, 51). GADD34 expression in macrophages also enhances
autophagy and suppresses apoptosis by regulating the mechanistic
target of rapamycin (mTOR) signaling pathway in response to com-
bined LPS stimulation and amino acid deprivation (52). It is, thus,
likely that according to the immunostimulation and the cell types
studied, major variations in the responses of GADD34-deficient cell
and animals can be observed.
The a2-adrenergic receptor agonist GBZ, which has been used to
treat hypertension, has been proposed to selectively disrupt the stress-
induced dephosphorylation of eIF2a by GADD34/PP1c without af-
fecting the related constitutive repressor of eIF2a phosphorylation
(CReP)–phosphatase complex. We showed that the proteostasis-
interfering drug GBZ efficiently inhibited endosomal TLR signaling
in vitro and partially mimicked GADD34 genetic inactivation by
controlling cytokine expression after endocytic TLR stimulation.
However, in agreement with Crespillo-Casado and collaborators
(23), we demonstrated that GBZ exerted its inhibitory activity on
TLR9 independently of GADD34 function. The capacity of GBZ
to block endocytic TLRs in both pDCs and B cells, twomajor cellular
effectors of autoimmunity, suggests that this drug could also be used
to treat different acute inflammatory diseases. The hypotensive activity
of GBZ was not involved in its inhibition of TLR signaling, which could
constitute a handicap in the clinic for many potential new indications;
on the other hand, 50% of SLE patients experience hypertension gener-
ally caused by obesity, kidney disease, and long-term steroid use. Thus,
the combined suppressive effect of GBZ on hypertension andTLR9 and
perhaps TLR7 could benefit patients with SLE or other specific IFN-
dependent diseases displaying similar pathologies with recurrent flares.
Novel GBZ-like drugs that lack a2-adrenergic receptor agonistic
activity have been designed and are currently being tested to treat
neurodegenerative conditions (20). The combined ability of these drugs
to interfere both with proteostasis and immunity might become a dual8 of 13
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 advantage for the treatment of neurodegenerative diseases, which often
feature increased neuronal cell death due to accumulation of misfolded
proteins and acute inflammation that further triggers tissue damage and
contributes to disease progression (20, 53). Such a dual effect could also
explain the protective role of GBZ treatment in DSS (dextran sulfate
sodium)–induced colitis or during sepsis induction in mice, which in-
volves both the control of inflammatory cytokine release and the stress
response in epithelial cells or hepatocytes (54–56).Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018We linked the inhibitory effect of GBZ on TLR9 signaling to a loss
in the expression ofCh25h, which encodes a cholesterol hydroxylase,
and failure of TLR9 to reach signaling endosomes and recruit IRF7.
In agreement with our findings, infection of Ch25h-deficient mice
with influenza virus leads to decreased production of IL-6 and type
I IFNs in the lungs, which enhances survival, suggesting that Ch25h
is required for normal activation of signaling cascades downstream
of TLR7 or TLR9. By decreasing Ch25h expression, GBZ thereforeFig. 7. 25-HC antagonizes GBZ inhibitory activity on TLR9. (A) CAL-1
cells were stimulated with 3 mM ODN 2216. GBZ was added at 50 mM. Im-
munofluorescence proximity ligation assays (iPLAs) were performed at
the indicated time points on the following pairs of proteins: TLR9/MyD88,
TLR9/VAMP3, and TLR9/IRF7. Scale bars, 10 mM. (B) CAL-1 cells were stim-
ulated with 3 mM ODN 2216 with or without GBZ (50 mM) and/or 25-
hydroxycholesterol (25-HC) (100 nM). iPLAs were performed at the indicated
time points on the following pairs of proteins: TLR9/MyD88, TLR9/VAMP3,
TLR9/MyD88 (3 hours) or TLR9/IRF7 (3 hours). Scale bars, 10 mM. (C) Rep-
resentative immunoblot for ribosomal protein S6 (S6) and associated TLR-
dependent phosphorylation in CAL-1 cells stimulated for 1 hour. Quantification
of the blots is shown on the right (n = 3 independent experiments). (D) TNF-a9 of 13secretion by CAL-1 cells stimulated with 3 mMODN 2216 for 3 hours with or without GBZ (50 mM) and/or 25-HC (100 nM) was measured by ELISA. Statistical significance was assigned
using two-tailed t test on at least three independent experiments (*P < 0.05; **P < 0.005; ***P < 0.0005).
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which appears to be sensitive to variations in 25-HC levels.
Whether Ch25h repression is linked to proteostasis perturbation
remains to be established. The transcription factor ATF3 is involved in
both inflammatory and metabolic pathways (47, 57) and contributes to
the ER stress response. ATF3 expression is augmented in response to
GBZ and could therefore contribute to the suppression of CH25H ex-
pression and associated TLR9 inhibition in nucleic acid–activated
cells. This phenomenon might be particularly relevant to pDCs and B
cells, which have a large ER adapted to protein secretion and depend on
stress response genes for their development and survival (58).
GBZ represents a pharmacological option to interfere with inflam-
matory and type I IFN–dependent diseases. By reducing the restoration
of protein synthesis during stress and changing the capacity of TLRs to
signal in immune cells, GBZ-like compounds could be used to treat both
proteotoxicity and associated inflammatory responses, which are key
features of autoimmunity and neurodegeneration. Our findings that
GBZ exerted its activity independently of GADD34 do not diminish
the attractiveness of the GADD34/PP1c complex as a druggable target
to alter cytokine production and proteostasis, but offer an alternative
therapeutic target for the treatment of autoinflammatory diseases. o
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 MATERIALS AND METHODS
Reagents and molecular biology
ODN2006, 2216, 1585, and 1826 andHMWand LMWpoly(I:C) are
from InvivoGen; LPS (Escherichia coli O55:B5), clonidine, chloro-
quine, D-(+)-galactosamine hydrochloride, and 25-HC are from Sigma-
Aldrich; and GBZ is from Tocris Bioscience. For qPCR, total RNAs
were extracted and purified using the RNeasy Mini Kit (Qiagen). Total
RNA (100 ng to 1 mg) was subjected to reverse transcription using
SuperScript II. Each gene transcripts were quantified by SYBRGreen
method with 7500 Fast (Applied Biosystems). The relative amount of
each transcript was determined by normalizing to internal house-
keeping gene expression. Primer sets are indicated in table S2.
Cell culture
BM-derivedDCswere differentiated in vitro from theBMof 6 to 8-week-
old male mice, using either FLT3 or GM-CSF. Flt3L-DCs were used for
experiments between days 6 and 7. Flt3L was produced using B16-Flt3L–
expressing cells (59). BMprogenitors were plated at 1.5 × 106 cells/ml, 4ml
per well in a six-well plate, and cultivated with RPMI (GIBCO), 10%
fetal calf serum(FCS) (Sigma-Aldrich), penicillin (100U/ml) and strepto-
mycin (100 mg/ml) (GIBCO), 50 mM b-mercaptoethanol (VWR), and
Flt3L. For sorted Flt3L-DCs, cells were gently harvested at day 7 with
cold phosphate-buffered saline (PBS) and 2% FCS, centrifuged at
1200 rpm for 5 min at 4°C, and then counted and stained for 30 min
at 4°C. Cells were sorted with a BD FACSAria SORP (BD Bio-
sciences). The gating strategy is illustrated in Fig. 2A. The cocktail
of antibodies used for sorting is listed in table S3. Cells were kept
on ice all the time. After sorting, cells were suspended in supplemented
Flt3L-DC medium at a concentration of 0.2 × 106 cells per well and
plated in a 96-well plate (U bottom). GM-CSF DCs were generated in
the same way using GM-CSF conditioned medium and collected for
experiments at day 6 of differentiation as previously described (14).
Mouse splenic cells
Splenocytes were dissociated injecting Liberase TL, followed by 25-min
incubation at 37°C. Cells were washed using magnetic-activated cell sort-Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018ing (MACS) buffer (1× PBS + 1% fetal bovine serum + 2 mM EDTA)
and passed in a 70-mm cell strainer, and then centrifuged for 5 min at
4°C. Red blood cells were lysed using the commercial buffer from
eBioscience. DCs were purified using CD11c+ selection kit from
Miltenyi. Splenic DCs were then resuspended in the same medium
as for Flt3L-DCs at 1 × 106 cells/ml and plated in a 12-well plate,
2 ml × well. B lymphocytes were purified using B Cell Isolation Kit, a
negative selection kit from Miltenyi. B cells were then resuspended in a
medium composed of RPMI (GIBCO), 10% FCS (Sigma-Aldrich), 1×
glutamine, 1× nonessential amino acids, 10 mM Hepes (all from
GIBCO), and 50 mM b-mercaptoethanol (VWR). Cells were plated
at 1 × 106 cells per well in a flat 96-well plate.
Human pDCs and B cells
Human peripheral blood mononuclear cells were isolated from whole
blood from volunteer donors by density gradient using Ficoll-Paque
PLUS (GE Healthcare), followed by a density gradient of Percoll PLUS
(GEHealthcare), to separate the lymphocytic fraction containing B cells
from the monocytic lineage fraction containing pDCs. Both cell types
were isolated using a negative selection kit from Miltenyi: B Cell Isola-
tion Kit II (human; for B cells) and Plasmacytoid Dendritic Cell Isola-
tion Kit II (human; for pDCs). pDCs were cultured at 0.5 × 106 cells/ml
in RPMI 1640medium containing 10% FCS and complemented with
IL-3 (10 ng/ml). B lymphocytes were cultured at 0.5 × 106 cells/ml in
RPMI 1640 medium containing 10% FCS and complemented with
penicillin (100 U/ml), streptomycin (100 mg/ml; GIBCO), and 1×
L-glutamine (GIBCO). Both cell types were plated in a 96-well
plate (U bottom).
Cell lines
HEK-Blue TLR cells (Invivogen) were grown in Dulbecco’s modified
Eagle’s medium, with 10% of FCS (Sigma-Aldrich) and a proper se-
lection of antibiotics. A20 cells were grown in RPMI (GIBCO), 10%
FCS (Sigma-Aldrich), and 50 mM b-mercaptoethanol (VWR). CAL-1
cells were grown in RPMI (GIBCO), 10% FCS (Sigma-Aldrich), 2 mM
L-glutamine, 1× nonessential amino acids, 10 mMHepes, and 1 mM so-
dium pyruvate (all from GIBCO). Cells were plated 16 hours before
the start of experiments in a 12-well plate at 1 × 106 cells/ml, 1ml ×well,
in a complete medium with 1% FCS. All cell lines were mycoplasma-
free and kept at 37°C and 5% CO2.
Flow cytometry
Cell suspensions were incubated with the antibody cocktail diluted
in cold fluorescence-activated cell sorting (FACS) buffer (PBS, 2%
FCS, and 2 mM EDTA) for 30 min at 4°C. For intracellular staining,
cells were permeabilized with FIX & PERM Kit (BD Biosciences).
Flow cytometry was conducted using the LSR 561 machine (BD
Biosciences), and data were analyzed with FlowJo (Tree Star). The
antibodies used are listed in tables S3 and S4.
Confocal microscopy and PLA
CAL-1 cells were harvested, centrifuged for 5 min at 4°C, then resus-
pended in prewarmed serum-free medium and dropped on a 12-mm
coverslip, and covered with 1% alcian blue. The coverslips were then
incubated for 20 min at 37°C and fixed with 3% paraformaldehyde.
iPLAs were performed using the Duolink Kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instruction. The following primary
antibodies are used: anti-TLR9 (H-100), Santa Cruz Biotechnology,
rabbit polyclonal (1:50); anti-Vamp3 (N-12), Santa Cruz Biotechnology,10 of 13
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 goat polyclonal (1:100); anti-human MyD88, R&D Systems, goat poly-
clonal (1:100); and anti-human IRF7 (G-8), Santa Cruz Biotechnology,
mouse IgG2a (1:100). Duolink PLA Probe anti-rabbit PLUS and anti-
goat or anti-mouseMINUS, conjugated with oligonucleotides, were used
as secondary antibodies. The samples were incubated in the ligation so-
lution consisting of Duolink Ligation Stock (1:5) and Duolink Ligase
(1:40). Detection of the amplified probe was done with the Duolink De-
tection Kit Orange. The images were taken with the confocal microscope
LSM580 (63×objective;Carl Zeiss) and accompanying imaging software.
Gene expression analysis
Total RNAwas isolated with the RNeasy kit (Qiagen). Complementary
DNA was synthesized with random hexamers and SuperScript II re-
verse transcriptase (Invitrogen). Real-time qPCR analysis was performed
with Applied Biosystems PRISM 7700 Sequence Detection System. The
list of the primers used is reported in table S4. For Affymetrixmicroarray
analysis, GM-CSF DCs were cultured in RPMI supplemented with
5% FCS, 50 mM b-mercaptoethanol, and GM-CSF. Cells differentiated
for 6 days were treated for 8 hours withmicrobial stimuli and harvested
before lysis. Control and P. mirabilis–treated DCs were incubated with
the bacteriostatic chloramphenicol to avoid bacterial growth. GBZ
was used at 50 mM. Hybridization to arrays (Affymetrix GeneChip
Mouse Gene 1.0 ST) and image scanning were performed according to
the Affymetrix Expression Analysis Technical Manual. Gene expression
microarray raw data were normalized using limmaGUI software (R/
Bioconductor). Data can be accessed through the Gene Expression
Omnibus (GEO) repository under accession number GSE90831.
Translation intensity measurement
Puromycin labeling for measuring the intensity of translation was
performed as previously described (41). Puromycin (P8833; min
98% thin-layer chromatography, cell culture–tested, and diluted in
PBS; Sigma-Aldrich) was added at 2.5 mg/ml in the culture medium,
and the cells were incubated for 15 min at 37°C and 5% CO2. Cells
were fixed and permeabilized with Cytofix/Cytoperm buffer (BD
Biosciences), stained with the anti-puromycin antibody (12D10) di-
rectly coupled with Alexa Fluor 488, and diluted in Perm/Wash
buffer (BD Biosciences). Flow cytometry was conducted using the
LSR 561 machine (BD Biosciences), and data were analyzed with
FlowJo (Tree Star).
Immunoblotting
Cells were lysed in 1% Triton X-100, 50 mM Hepes, 10 mM NaCl,
2.5 mMMgCl2, 2 mM EDTA, and 10% glycerol and supplemented
with cOmplete Mini Protease Inhibitor Cocktail Tablets (Roche). Pro-
tein quantification was performed using the BCA (bicinchoninic acid)
Protein Assay (Pierce). Twenty to 25 mg of Triton X-100 soluble mate-
rial was loaded on 10% SDS–polyacrylamide gel electrophoresis before
immunoblotting and chemiluminescence detection (SuperSignal West
Pico Chemiluminescent Substrate, Pierce). The rabbit polyclonal anti-
body against eIF2a (D7D3) was purchased from Cell Signaling Tech-
nology. The rabbit polyclonal antibody against phosphorylated eIF2a
(Ser51) was fromAbcam.Mousemonoclonal antibodies against b-actin
were from Sigma-Aldrich and Upstate Biotechnology. Secondary anti-
bodies were purchased from Jackson ImmunoResearch Laboratories.
Cytokine measurement
Mouse IFN-b quantification in culture supernatant was performed
using the Mouse Interferon Beta ELISA kit (PBL InterferonSource).Perego et al., Sci. Signal. 11, eaam8104 (2018) 23 January 2018Mouse IL-6, TNF-a, IL-10, human TNF-a, and human IFN-a were
quantified using an appropriate ELISA kit (eBioscience) according to
the manufacturer’s instructions.
Animal studies
WT C57BL/6 mice were purchased from The Jackson Laboratory.
GADD34DC/DC mice (FVB background) and WT littermate were origi-
nally obtained from L. Wrabetz (DIBIT, San Raffaele Scientific Institute,
Milan) andmaintained in the animal facility of Centre d’Immunologie de
Marseille-Luminy (CIML) under specific pathogen–free conditions. This
study was carried out in strict accordance with the recommendations in
theGuide for theCare andUseof LaboratoryAnimals of theFrenchMin-
istry of Agriculture and of the European Union. Animals were housed in
CIML animal facilities accredited by the French Ministry of Agriculture
to perform experiments on live mice. All animal experiments were ap-
proved by Direction Départementale des Services Vétérinaires des
Bouches du Rhône (approval number A13-543). All efforts were made
to minimize animal suffering.
TMPD model
WT female 6-week-old C57BL/6 mice were injected intraperitoneally
with 500 ml of TMPD (Sigma-Aldrich) or PBS. From days 1 to 13, mice
were injected intraperitoneally every 2 days with GBZ or PBS/dimethyl
sulfoxide (DMSO) (2 mg/kg). Mice were injected intraperitoneally on
day 7 with ODN 1585 (50 mg/20 g of mouse) or PBS. Mice were sacri-
ficed at day 14 or after 6 months. At day 14, PECs were taken for flow
cytometry analysis. After 6 months, kidneys were taken for immuno-
histochemistry. During the 6 months between injection and sacrifice,
blood serum collection was performed once a month, from 2 months
after the injection of TMPD up to 1 week before the animal sacrifice.
Serum was used to evaluate the concentration of circulating autoanti-
bodies. Monitoring of anti-RNA autoantibody titer was performed by
coatingELISAplateswith 50ml perwell ofmouseRNAorDNA(5mg/ml)
in PBS, which were incubated overnight at 4°C. The next day, plates were
incubated with 1:50 or 1:100 diluted serum samples in working solution
(PBS+0.05%Tween 20+1%bovine serumalbumin), and the assaywas
developed with horseradish peroxidase–labeled goat anti-mouse IgG
(SouthernBiotech) (60).
Cytokine shock model
WT female 8-week-old C57BL/6 mice were injected intraperitoneally
with GBZ, clonidine, or PBS/DMSO (2 mg/kg). One hour later, they
were injected intraperitoneally with 20 mg per mouse of D-GalN and
ODN 1826 (50 mg/20 g) (or PBS). Mice survival was checked every
12 hours for up to 48 hours. For some experiments, blood sera were col-
lected 1 and 3 hours after the injection of D-GalN. The serum was used
to measure circulating cytokines (TNF-a, IL-6, IFN-b, IL-10, and IL-12).
For some experiments, the liver was collected for immunohistochemistry
after 2 days. For intraperitoneal injections, 1-ml syringes and 25-gauge
needles were used. Blood was collected from the cheek with an 18-gauge
needle; for the TMPD model, no more than 200 ml was collected each
time in accordance with ethical requirements.
Tissue histology
Mousekidneys and liverswere fixed in10%buffered formalin for24hours,
dehydrated, and embedded in paraffin. Tissue sections (3.5 mm) were cut
using the Leica microtome RM2245. Hematoxylin and eosin staining
was performed automatically with a Leica AutoStainer XL. Finally,
the slides were mounted with “entellan” and kept at room temperature.11 of 13
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 Biopsies were analyzed by an anatomopathologist, who assigned the
clinical score while blinded to the treatments. Pictures were taken with
a Nikon Eclipse.
Anatomopathology scoring system for liver damage
Lobular inflammation was assessed as follows: 0, no inflammation; 1,
mild lobular inflammation (<10% of liver parenchyma); 2, moderate
lobular inflammation (10 to 50% of liver parenchyma); and 3, severe
lobular inflammation (>50% of liver parenchyma). Portal inflamma-
tion was assessed as follows: 0, no portal inflammation; 1, mild portal
inflammation (less than one-third of portal tracts); 2, moderate portal
inflammation (about 50% of portal tracts); and 3, severe portal inflam-
mation (greater than two-thirds of portal tracts). The inflammation
score was obtained by adding the portal and lobular inflammation
scores. Necrosis was assessed as follows: 0, no necrosis; 1, <10% necrosis
of liver parenchyma; 2, 10 to 25% necrosis of liver parenchyma; and 3,
>25% necrosis of liver parenchyma. The total histological score was
obtained by adding the inflammation and necrosis scores.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software.
When several conditions were compared, we performed a one-way
analysis of variance (ANOVA), followed by a Tukey range test to assess
the significance among pairs of conditions. When only two conditions
were tested, we performed Student’s t test orWelch’s t test (according to
the validity of the homoscedasticity hypothesis). Statistical analysis
on survival curves was performed using log-rank test, followed by the
Benjamini-Yekutieli correction when required. o
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Fig. S1. GBZ inhibits TLR9 signaling in B cells.
Fig. S2. TMPD and CpG synergize to promote inflammation.
Fig. S3. GBZ does not inhibit endosomal acidification or protein synthesis.
Fig. S4. GBZ and 25-HC do not reduce TLR9 abundance in pDCs.
Table S1. List of genes in DCs with increased expression in response to poly(I:C) or P. mirabilis
that is inhibited by GBZ.
Table S2. List of the primers used for gene expression analysis by qPCR.
Table S3. List of the antibodies used for sorting DC1, DC2, and pDCs from Flt3L-DC culture.
Table S4. List of the antibodies used for flow cytometry.20REFERENCES AND NOTES
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from hypertension and that guanabenz and related compounds could, thus, have dual benefits for these patients.
such that TLR9 did not reach endosomes where it is fully activated. The authors note that many lupus patients suffer
However, guanabenz did not inhibit TLR9 by affecting GADD34 activity, but rather by altering cholesterol metabolism 
erroneously recognized by the immune system, and guanabenz reduced symptom severity in a mouse model of lupus.
IFN secretion from immune cells in response to DNA. TLR9 is implicated in autoimmune diseases in which self-DNA is 
. found that guanabenz inhibited the activation of TLR9, a receptor that induces type Iet al. Perego βcytokines and IFN-
be mediated by the inhibition of GADD34, a phosphatase subunit that promotes the production of proinflammatory 
The FDA-approved antihypertensive drug guanabenz also has anti-inflammatory properties, which are thought to
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